30 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 Mar 19
Regulation FD Disclosure
2:02pm
suppression (T-Reg, MDSC) § Chronic antigen stimulation tumor cells § Bolt-on transgene may augment many types BOXR components of T cell therapies (ACTR, CAR … suppression (T-Reg, MDSC) § Chronic antigen stimulation tumor cells § Bolt-on transgene may augment many types BOXR components of T cell therapies
8-K
EX-99.1
COGT
Cogent Biosciences Inc
13 Jan 20
Regulation FD Disclosure
7:42am
effects of the TME, including: Competition for metabolites Exhaustion due to chronic stimulation Resistance to immunosuppressive cell types Novel bolt … : Reduced Tumor Burden in Mouse Xenografts Chronic Stimulation (Hep3B) Low Glucose (JHH7) PD-L1 High and Low Glucose (NCI-H446) Control GPC3 CAR T
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 Jan 19
Regulation FD Disclosure
8:02am
shortages Chronic stimulation Secreted T cell inhibitors ACTR parent 4-1BB BOXR constructs Score IL-2 Prolif IL-2 Prolif IL-2 Prolif Prolif Prolif PGE2 … BOXR947 BOXR1012 BOXR1045 BOXR1108 Exhaustion due to chronic stimulation (multiple) (multiple)
Business Considerations
Building for Commercialization
8-K
EX-99.1
COGT
Cogent Biosciences Inc
5 Nov 19
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
2:16pm
, including metabolic competition, immune suppressor cells, and exhaustion due to chronic stimulation. Once discovered, BOXR transgenes are designed
8-K
EX-99.1
COGT
Cogent Biosciences Inc
11 Aug 20
Unum Therapeutics Reports Second Quarter 2020
5:02pm
, including reduced life span and chronic conditions, and there are limited treatment options available. Unum expects to initiate clinical testing
8-K
EX-99.1
kjh3kddfj7chbag
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
8-K
54vj989w52bgquq 0cz
11 Dec 23
Other Events
8:04am
8-K
EX-99.2
9umyo6d44pou
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am
8-K
EX-99.2
5959 agz1d3h
5 Oct 20
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
9:08am
8-K
EX-99.1
dtdsujv 1jt83h1t25
12 Aug 19
Unum Therapeutics Reports Second Quarter 2019 Financial Results
4:12pm
8-K
EX-99.2
dje8gpvobvxfee8u02b
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
424B5
9s4h7q851l
13 Jun 22
Prospectus supplement for primary offering
6:11am
424B5
ukyi1aqckdezh
15 Jun 22
Prospectus supplement for primary offering
5:16pm
424B5
nf0prd8pwe8pkmumqoca
20 Mar 20
Prospectus supplement for primary offering
8:26am